6,950
Participants
Start Date
March 20, 2017
Primary Completion Date
September 30, 2020
Study Completion Date
May 1, 2021
Pharmacogenomic testing
"The pharmacogenomic panel to be used incorporates 48 genetic variants for the following 13 pharamacogenes: CYP2B6 (cytochrome P450), CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), NUDT15 (Nudix hydrolase), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex)."
Medical University of Vienna, Vienna
University of Patras, Pátrai
Centro di Riferimento Oncologico, Aviano
Leiden University Medical Center, Leiden
University of Ljubljana, Ljubljana
Servicio Andaluz de Salud, Granada
University of Liverpool, Liverpool
University of Liverpool
OTHER
Medical University of Vienna
OTHER
Centro di Riferimento Oncologico - Aviano
OTHER
Andaluz Health Service
OTHER_GOV
University of Patras
OTHER
University of Ljubljana
OTHER
Karolinska Institutet
OTHER
The Golden Helix Foundation
UNKNOWN
Royal Dutch Pharmacists Association (KNMP)
UNKNOWN
Bio.Logis Genetic Information Management
UNKNOWN
University Paul Sabatier of Toulouse
OTHER
Uppsala University
OTHER
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
OTHER
Federal Institute for Drugs and Medical Devices
UNKNOWN
St. Antonius Hospital
OTHER
J.J.Swen
OTHER